Suchergebnisse - "Smith, Patrick F"

PubPharm (42)

1

Respiratory syncytial virus-A dynamics and the effects of lumicitabine, a nucleoside viral replication inhibitor, in experimentally infected humans

enthalten in: The Journal of antimicrobial chemotherapy | 2019

von Patel, K. | Kirkpatrick, C. | Nieforth, K. | +10

2

A pharmacokinetic/viral kinetic model to evaluate treatment of chronic HCV infection with a non-nucleoside polymerase inhibitor

enthalten in: Antiviral therapy | 2018

von Canini, L. | Lemenuel-Diot, A. | Brennan, B. | +2

3

A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers

enthalten in: British journal of clinical pharmacology | 2017

von Smith, P. | Krishnarajah, J. | Nunn, P. | +6

4

Applications of Influenza Viral Kinetic Modeling in Drug Development

enthalten in: Current pharmacology reports | 2017

von Lovern, M. | Minton, S. | Patel, K. | +3

5

Applications of Influenza Viral Kinetic Modeling in Drug Development

enthalten in: Current pharmacology reports | 2017

von Lovern, M. | Minton, S. | Patel, K. | +3

6

Interdisciplinary pharmacometrics linking oseltamivir pharmacology, influenza epidemiology and health economics to inform antiviral use in pandemics

enthalten in: British journal of clinical pharmacology | 2017

von Kamal, M. | Smith, P. | Chaiyakunapruk, N. | +12

7

Erratum for Kamal et al., A Drug-Disease Model Describing the Effect of Oseltamivir Neuraminidase Inhibition on Influenza Virus Progression

enthalten in: Antimicrobial agents and chemotherapy | 2016

von Kamal, M. | Gieschke, R. | Lemenuel-Diot, A. | +3

ErratumFor: Antimicrob Agents Chemother. 2015 Sep;59(9):5388-95. - PMID 26100715

8

Safety and Upper Respiratory Pharmacokinetics of the Hemagglutinin Stalk-Binding Antibody VIS410 Support Treatment and Prophylaxis Based on Population Modeling of Seasonal Influenza A Outbreaks

enthalten in: EBioMedicine | 2016

von Wollacott, A. | Boni, M. | Szretter, K. | +8

CommentIn: EBioMedicine. 2016 Mar;5:16-7. - PMID 27077102

9

Modelling the interaction between danoprevir and mericitabine in the treatment of chronic HCV infection

enthalten in: Antiviral therapy | 2016

von Canini, L. | Guedj, J. | Chatterjee, A. | +3

10

A drug-disease model describing the effect of oseltamivir neuraminidase inhibition on influenza virus progression

enthalten in: Antimicrobial agents and chemotherapy | 2015

von Kamal, M. | Gieschke, R. | Lemenuel-Diot, A. | +3

ErratumIn: Antimicrob Agents Chemother. 2016 Mar;60(3):1953. - PMID 26921415

1
2
3
4
5
Nächster »
[5]